Forbion Capital Partners of the Netherlands has secured €460 million for an oversubscribed fifth fund, the proceeds of which will be used to build a portfolio of 15 companies developing new medical therapeutics. About 80% of the investments are expected to be made in Europe, with the balance targeting assets in North America.
